Literature DB >> 1486880

Pathologic hyperprolactinemia.

M E Molitch1.   

Abstract

Unlike other pituitary hormones, PRL is under tonic inhibition by the hypothalamus by way of the PRL inhibitory factor, dopamine. GAP and GABA may also be inhibitory. PRL-releasing factors include TRH and VIP and possibly others. Circulating PRL is predominantly monomeric, although some patients with hyperprolactinemia appear to have increased quantities of the less biologically active polymeric forms. PRL is secreted episodically, with an increase in the amplitude of the secretory pulses with sleep. A transitory increase also occurs in response to the protein component of meals. Basal PRL levels increase in response to the hormonal milieu of pregnancy, and suckling postpartum triggers PRL release. Pathologic increases of PRL owing to hypothalamic dysregulation occur with a variety of medications, including the neuroleptics, metoclopramide, antidepressants, methyldopa, reserpine and verapamil, abuse of opiates and cocaine, renal insufficiency, cirrhosis, hypothyroidism, adrenal insufficiency, neurogenic stimulation, and idiopathically. Hyperprolactinemia also may occur from structural lesions of the stalk and hypothalamus, which cause disinhibition with or without maintenance of PRF activity, ectopic neoplasm production, and, most commonly, from prolactinomas. Diagnostic testing consists of routine chemistry and thyroid testing and imaging with MRI or CT. Dopamine agonists are the treatment of choice of prolactinomas of all sizes. Transsphenoidal surgery is an alternative for the patient who does not respond to medical therapy or who wishes definitive tumor removal, realizing that long-term cure is achieved in only 50% to 60% of patients with microadenomas and a much lower number in those with macroadenomas. Radiotherapy is reserved for patients who do respond to either medical or surgical treatment. Patients wishing to become pregnant usually are treated with bromocriptine, although prepregnancy surgical debulking may be advisable for those with large macroadenomas to reduce problems with tumor enlargement.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1486880

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  18 in total

1.  Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center.

Authors:  Sema Ciftci Dogansen; Seher Tanrikulu; Gulsah Yenidunya Yalin; Sema Yarman
Journal:  Endocrine       Date:  2018-02-05       Impact factor: 3.633

2.  Microprolactinomas: why requiem for surgery?

Authors:  A Liuzzi; G Oppizzi
Journal:  J Endocrinol Invest       Date:  1996-03       Impact factor: 4.256

3.  Treatment of prolactinomas by transsphenoidal adenomectomy.

Authors:  H Vierhapper; T Czech; C Matula; W Raber
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

4.  Pergolide as primary therapy for macroprolactinomas.

Authors:  J J Orrego; W F Chandler; A L Barkan
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

5.  Postmortem prolactin as a marker of antemortem stress.

Authors:  T J Jones; M J Hallworth
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

Review 6.  Hyperprolactinemia in men: clinical and biochemical features and response to treatment.

Authors:  Michele De Rosa; Stefano Zarrilli; Antonella Di Sarno; Nicola Milano; Maria Gaccione; Bartolomeo Boggia; Gaetano Lombardi; Annamaria Colao
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

7.  Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma).

Authors:  M Berezin; I Shimon; M Hadani
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

Review 8.  Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife.

Authors:  Jay Jagannathan; Chun-Po Yen; Nader Pouratian; Edward R Laws; Jason P Sheehan
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

9.  Effect of human prolactin administration on gonadotropin and thyrotropin secretion in normal men.

Authors:  M E Molitch; R W Rebar; C P Barsano
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

Review 10.  The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.

Authors:  Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.